--- title: "BioCardia | 8-K: FY2026 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/286562387.md" datetime: "2026-05-15T12:08:30.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286562387.md) - [en](https://longbridge.com/en/news/286562387.md) - [zh-HK](https://longbridge.com/zh-HK/news/286562387.md) --- # BioCardia | 8-K: FY2026 Q1 Revenue: USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0. EPS: As of FY2026 Q1, the actual value is USD -0.21. #### Operational Metrics - **Net Cash Used in Operations**: Net cash used in operations was approximately $1.7 million for the three months ended March 2026, an increase from approximately $1.6 million in the three months ended March 2025, primarily due to the timing of supplier payments . - **Research and Development Expenses**: Research and development expenses decreased to approximately $1.2 million for the three months ended March 2026, down from approximately $1.5 million in the three months ended March 2025 . This decrease was primarily due to the closeout of the CardiAMP HF Trial, partially offset by early enrollment in the CardiAMP HF II Trial and regulatory activities for CardiAMP in Japan . - **Selling, General and Administrative Expenses**: Selling, general and administrative expenses decreased to approximately $1.0 million for the three months ended March 2026, compared to approximately $1.2 million in the three months ended March 2025, primarily due to lower professional service fees . - **Operating Loss**: Operating loss was - $2,266 thousand for the three months ended March 31, 2026, an improvement from - $2,726 thousand for the same period in 2025 . - **Net Loss**: Net loss was approximately - $2.3 million for the three months ended March 2026, an improvement from approximately - $2.7 million in the three months ended March 2025 . The specific net loss figures were - $2,259 thousand for the three months ended March 31, 2026, compared to - $2,712 thousand for the same period in 2025 . - **Net Loss Per Share**: Net loss per share, basic and diluted, was - $0.21 for the three months ended March 31, 2026, compared to - $0.59 for the same period in 2025 . #### Balance Sheet Metrics - **Cash and Cash Equivalents**: BioCardia, Inc. ended the quarter with cash and cash equivalents totaling $951 thousand as of March 31, 2026, a decrease from $2,496 thousand as of December 31, 2025 . - **Total Assets**: Total assets were $1,712 thousand as of March 31, 2026, down from $3,413 thousand as of December 31, 2025 . - **Current Liabilities**: Current liabilities increased to $2,778 thousand as of March 31, 2026, from $2,432 thousand as of December 31, 2025 . - **Total Stockholders’ Equity (Deficit)**: Total stockholders’ equity (deficit) was - $1,066 thousand as of March 31, 2026, compared to $895 thousand as of December 31, 2025 . #### Unique Metrics / Operational Highlights - **CardiAMP® autologous cell therapy (BCDA-01) for ischemic heart failure**: The PMDA provided additional questions in February and, following a Formal Clinical Consultation in April, determined that the clinical safety and efficacy evidence is likely sufficient to support market clearance in Japan . BioCardia, Inc. received the preliminary Advisory Record from PMDA in May and is preparing for Shonin submission . The FDA expressed no concerns on safety and confirmed that Premarket Approval (PMA) continues to be the appropriate regulatory pathway, recommending the continuation of the CardiAMP HF II trial as a confirmatory study . Patients are being screened, consented, and randomized at four active CardiAMP HF II clinical sites . - **CardiAMP autologous cell therapy (BCDA-02) for chronic myocardial ischemia with refractory angina**: Primary results of this cohort have been accepted for oral presentation at Euro PCR in Q2 2026 . - **Helix™ Biotherapeutic Delivery System**: BioCardia, Inc. announced a Pre-Submission to the FDA in February for approval of its Helix Transendocardial Delivery Catheter . In May, the FDA agreed on two pathways for Helix marketing clearance, raising no concerns on safety data or device performance, and suggested a follow-on pre-submission for DeNovo pathway approval . - **Intellectual Property**: BioCardia, Inc. announced the Japan Patent, “Target Site Selection, Entry, and Update with Automatic Remote Image Annotation,” in March, adding protection to its Heart3D™ Fusion Imaging software . #### Outlook / Guidance BioCardia, Inc. anticipates an oral presentation for CardiAMP for Chronic Myocardial Ischemia at Euro PCR in Q2 2026 . The company also expects the Japan PMDA Shonin Submission for Approval in Q4 2026 . ### Related Stocks - [BCDA.US](https://longbridge.com/en/quote/BCDA.US.md) ## Related News & Research - [Key facts: CardiAMP advances in US, Japan; FDA flags two Helix paths](https://longbridge.com/en/news/286637684.md) - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [Correction: NextNRG to Host First Quarter 2026 Financial Results Conference Call on May 18, 2026 at 9:00 a.m. ET | NXXT Stock News](https://longbridge.com/en/news/286673001.md) - [Acenta Group delays Q1 interim report release to May 29, 2026](https://longbridge.com/en/news/287031560.md)